Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboxymethylpullulan-phenylglycyl-doxorubicin conjugate
- Development stage
- Preclinical
- Lead developer
- Shionogi
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Carboxymethylpullulan-phenylglycyl-doxorubicin conjugate is an experimental **polymer-drug conjugate** consisting of doxorubicin linked to carboxymethylpullulan through a phenylglycyl spacer. It was reported by **Shionogi** as a macromolecular anticancer conjugate designed for intravenous delivery and preferential retention in solid tumors via the enhanced permeability and retention effect, with subsequent antitumor activity attributable to the doxorubicin payload. In murine models, the conjugate showed improved antitumor efficacy and lower systemic toxicity than free doxorubicin, particularly in solid tumor and metastatic models, but it does not appear to have become a marketed product.
- Other names
- carboxymethylpullulan-phenylglycyl-doxorubicin conjugate
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on carboxymethylpullulan-phenylglycyl-doxorubicin conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboxymethylpullulan-phenylglycyl-doxorubicin conjugate.